Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy

Ma,Ying; Yuan,Yujun; Ma,Xianglin; Tang,Boru; Hu,Ximei; Feng,Juan; Tian,Li; Ji,Yaohua; Dou,Xiaoguang

doi:10.3892/etm.2016.3365

August-2016 Volume 12 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2016 Volume 12 Issue 2

Full Size Image

Article

Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy

Authors:
- Ying Ma
- Yujun Yuan
- Xianglin Ma
- Boru Tang
- Ximei Hu
- Juan Feng
- Li Tian
- Yaohua Ji
- Xiaoguang Dou
View Affiliations / Copyright

Affiliations: Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110817, P.R. China, Department of General Surgery, The Third People's Hospital of Wafangdian, Wafangdian, Liaoning 116300, P.R. China, Department of Geriatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110817, P.R. China, Department of Virus, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110817, P.R. China, Department of Infectious Disease, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110817, P.R. China
Pages: 847-853
|
Published online on: May 19, 2016

https://doi.org/10.3892/etm.2016.3365
Expand metrics +

Abstract

The aim of the present study was to investigate the correlation between feature and genotype with regard to the tyrosine-methionine-aspartate-aspartate (YMDD) mutation in chronic hepatitis B patients after lamivudine (LAM) therapy. A total of 30 patients with chronic hepatitis B were recruited, who underwent one year of LAM therapy. The patients' alanine aminotransferase (ALT) level and hepatitis B envelope antigen (HBeAg) seroconversion were evaluated, hepatitis B virus (HBV) DNA was genotyped using a new genotyping method and YMDD mutations were analyzed prior to treatment and at 6 and 12 months after LAM treatment. Furthermore, the secondary protein structure of the HBV DNA polymerase gene (P gene) was analyzed. Following treatment, the results suggested that LAM therapy improved ALT normalization. There was no correlation between clinical effects and ALT level before treatment. After 12 months treatment, the rate of HBeAg loss increased and the rate of HBeAg seroconversion decreased linearly with the rise of baseline ALT level. While ALT normalization and HBeAg seroconversion were highest in patients with HBV genotype B, HBeAg loss and HBVDNA loss were highest in those with genotype C. The effect was predominant in genotype D. No YMDD mutations were identified prior to 6 months of LAM therapy. The rate of YMDD mutations after 12 months LAM therapy was 12.12%. Two patients with rtM204V + rtL180M belonged to genotype C and another patient with rtL180M alone belonged to genotype D. The turn of secondary protein structure of P gene changed to β sheet when a rtM204V mutation occurred, and no change of secondary protein structure was associated with the rtL180M mutation. Thus, the present results indicate that one year of LAM therapy is able to improve ALT normalization. Long‑term LAM therapy may induce YMDD mutation and drug resistance.

View Figures

View References

1	Ghaziani T, Sendi H, Shahraz S, Zamor P and Bonkovsky HL: Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome. World J Gastroenterol. 20:14142–14155. 2014. View Article : Google Scholar : PubMed/NCBI
2	Lai CL, Ratziu V, Yuen MF and Poynard T: Viral hepatitis B. Lancet. 362:2089–2094. 2003. View Article : Google Scholar : PubMed/NCBI
3	Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L and Häussinger D: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 334:1422–1427. 1996. View Article : Google Scholar : PubMed/NCBI
4	Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Viral Hepat. 11:97–107. 2004. View Article : Google Scholar : PubMed/NCBI
5	Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S and Nishiguchi S: Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: Analyses of the polymerase gene and full-length sequences. J Med Virol. 79:1664–1670. 2007. View Article : Google Scholar : PubMed/NCBI
6	França PH, Coelho HS, Brandão CE, Segadas JA, Quintaes RF, Carrilho FJ, Ono-Nita S, Mattos AA, Tovo C, Gouvea VS, et al: The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: An opportunity for therapy reevaluation. J Med Biol Res. 40:1605–1614. 2007. View Article : Google Scholar
7	Yen YH, Lu SN, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS and Lee CM: Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy. Liver Int. 27:1349–1355. 2007. View Article : Google Scholar : PubMed/NCBI
8	Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N and Condreay LD: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine clinical investigation group. Hepatology. 27:1670–1677. 1998. View Article : Google Scholar : PubMed/NCBI
9	Seta T, Yokosuka O, Imazeki F, Tagawa M and Saisho H: Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol. 60:8–16. 2000. View Article : Google Scholar : PubMed/NCBI
10	Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, et al: A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med. 339:61–68. 1998. View Article : Google Scholar : PubMed/NCBI
11	Song BC, Suh DJ, Lee HC, Chung YH and Lee YS: Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 32:803–806. 2000. View Article : Google Scholar : PubMed/NCBI
12	Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S and Schiff E: Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 37:748–755. 2003. View Article : Google Scholar : PubMed/NCBI
13	Ito K, Tanaka Y, Orito E, Hirashima N, Ide T, Hino T, Kumashiro R, Kato A, Nukaya H, Sakakibara K, et al: Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection. Clin Infect Dis. 38:490–495. 2004. View Article : Google Scholar : PubMed/NCBI
14	Menéndez-Arias L, Álvarez M and Pacheco B: Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: Mechanism of action and resistance. Curr Opin Virol. 8:1–9. 2014. View Article : Google Scholar : PubMed/NCBI
15	Huang ZM, Huang QW, Qin YQ, He YZ, Qin HJ, Zhou YN, Xu X and Huang MJ: YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol. 11:867–870. 2005. View Article : Google Scholar : PubMed/NCBI
16	Ma Y, Ding Y, Juan F and Dou XG: Genotyping the hepatitis B virus with a fragment of the HBV DNA polymerase gene in Shenyang, China. Virol J. 8:3152011. View Article : Google Scholar : PubMed/NCBI
17	Palumbo E: Hepatitis B genotypes and response to antiviral therapy: A review. Am J Ther. 14:306–309. 2007. View Article : Google Scholar : PubMed/NCBI
18	Damerow H, Yuen L, Wiegand J, Walker C, Bock CT, Locarnini S and Tillmann HL: Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol. 82:1850–1858. 2010. View Article : Google Scholar : PubMed/NCBI
19	Li SY, Qin L, Zhang L, Song XB, Zhou Y, Zhou J, Lu XJ, Cao J, Wang LL, Wang J and Ying BW: Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China. Med Sci Monit. 17:PH75–PH80. 2011. View Article : Google Scholar : PubMed/NCBI
20	Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J and Gray DF: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut. 46:562–568. 2000. View Article : Google Scholar : PubMed/NCBI
21	Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M and Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 341:1256–1263. 1999. View Article : Google Scholar : PubMed/NCBI
22	Chien RN, Liaw YF and Atkins M: Lamivudine as initial treatment for chronic hepatitis B in the United States. Hepatology. 30:770–774. 1999. View Article : Google Scholar : PubMed/NCBI
23	Kim IH, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG, Choi CS and Kim HC: Treatment outcomes of clevudine versus lamivudine at week 48 in naïve patients with HBeAg positive chronic hepatitis B. J Korean Med Sci. 25:738–745. 2010. View Article : Google Scholar : PubMed/NCBI
24	Bae SH, Baek YH, Lee SW and Han SY: Treatment efficacy of clevudine, entecavir and lamivudine in treatment-naive patients with HBeAg-positive chronic hepatitis B. Korean J Gastroenterol. 56:365–372. 2010.(In Korean). View Article : Google Scholar : PubMed/NCBI
25	Ismail S, Hafez HA, Darweesh SK, Kamal KH and Esmat G: Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy. Ann Gastroenterol. 27:380–386. 2014.PubMed/NCBI
26	Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi M and Andreone P: Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology. 32:1145–1153. 2000. View Article : Google Scholar : PubMed/NCBI
27	Kobayashi S, Ide T and Sata M: Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol. 34:584–586. 2001. View Article : Google Scholar : PubMed/NCBI
28	Lee SH, Kim HS, Byun IS, Jeong SW, Kim SG, Jang JY, Kim YS and Kim BS: Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. J Med Virol. 84:217–222. 2012. View Article : Google Scholar : PubMed/NCBI
29	Tan Y, Ding K, Su J, Trinh X, Peng Z, Gong Y, Chen L, Cui Q, Lei N, Chen X and Yu R: The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: A systematic review and meta-analysis. PLoS One. 7:e327892012. View Article : Google Scholar : PubMed/NCBI
30	Rahimi R, Hosseini SY, Fattahi MR, Sepehrimanesh M, Safarpour A, Malekhosseini SA, Nejabat M, Khodadad M and Ardebili M: YMDD motif mutation profile among patients receiving liver transplant due to hepatitis B virus infection with long term lamivudine/immunoglobulin therapy. Hepat Mon. 15:e271202015. View Article : Google Scholar : PubMed/NCBI
31	Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H and Iino S: A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology. 33:218–223. 2001. View Article : Google Scholar : PubMed/NCBI
32	Damerow H, Yuen L, Wiegand J, Walker C, Bock CT, Locarnini S and Tillmann HL: Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol. 82:1850–1858. 2010. View Article : Google Scholar : PubMed/NCBI
33	Xu G, You Q, Pickerill S, Zhong H, Wang H, Shi J, Luo Y, You P, Kong H, Lu F and Hu L: Application of PCR-LDR-nucleic acid detection strip in detection of YMDD mutation in hepatitis B patients treated with lamivudine. J Med Virol. 82:1143–1149. 2010. View Article : Google Scholar : PubMed/NCBI